Understanding the uncommon: Insights into thymoma associated immunodeficiency

Area of Science:

• Immunology
• Oncology
• Clinical Medicine

Background:

• Thymoma-associated immunodeficiency (TAI) is a rare acquired adult-onset immunodeficiency.
• It encompasses classic Good syndrome (GS) with thymoma and hypogammaglobulinemia, and non-classic forms.
• TAI involves B- and T-cell deficiencies, leading to significant morbidity and mortality, with unclear immunopathology.

Purpose of the Study:

• To analyze clinical features, laboratory findings, immunological profiles, and treatment outcomes in 21 TAI patients.
• To investigate associated comorbidities and complications in TAI.
• To explore anti-cytokine antibodies in a subset of TAI patients.

Main Methods:

• Retrospective review of 21 TAI patients diagnosed between January 1999 and December 2023.
• Extraction of clinical, laboratory, treatment, and outcome data from medical records.
• Anti-cytokine antibody profiling in seven consenting patients.

Main Results:

• TAI predominantly affected females (57.1%), with a mean age at diagnosis of 61.3 years.
• 19 patients had classic GS; common comorbidities included bronchiectasis (57.1%), sinusitis (23.8%), and other malignancies (23.8%).
• Autoimmune conditions (47.6%) and opportunistic infections were frequent; 9 patients died within a median of 4.2 years.

Conclusions:

• TAI is linked to substantial morbidity and mortality.
• The syndrome predisposes patients to opportunistic infections, autoimmune complications, and malignancies.
• Understanding TAI's immunopathology is critical for improving patient outcomes.